Overview
ALGS market data
Price History
ALGS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.45 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.49 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,919.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.98 – $13.69 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $47.8M · P/B 1.07 · P/S 10.15.
Company News
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV InfectionBenzinga · Aug 12, 2026, 8:24 PM
Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.Benzinga · Aug 6, 2026, 5:07 PM
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M EstimateBenzinga · Aug 6, 2026, 12:02 PM
8-K filing — Aligos Therapeutics, Inc. (ALGS)SEC EDGAR · Aug 6, 2026, 12:00 PM
Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus InfectionBenzinga · Jul 13, 2026, 12:01 PM
Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy DesignationBenzinga · Jul 6, 2026, 8:10 PM
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45Benzinga · May 28, 2026, 5:18 PM
Aligos Therapeutics Reports 40% Of HBeAg+ Chronic HBV Patients Achieve HBsAg Reduction After 48 Weeks Of Pevifoscorvir SodiumBenzinga · May 27, 2026, 7:31 AM
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20Benzinga · May 21, 2026, 2:20 PM